Biotechnology to improve health in developing countries - A review

被引:8
作者
Acharya, T [1 ]
Kennedy, R [1 ]
Daar, AS [1 ]
Singer, PA [1 ]
机构
[1] Univ Toronto, Joint Ctr Bioeth, Toronto, ON M5G 1L4, Canada
来源
MEMORIAS DO INSTITUTO OSWALDO CRUZ | 2004年 / 99卷 / 04期
关键词
biotechnology; developing countries; global health;
D O I
10.1590/S0074-02762004000400001
中图分类号
R38 [医学寄生虫学]; Q [生物科学];
学科分类号
07 ; 0710 ; 09 ; 100103 ;
摘要
The growing health disparities between the developing and the developed world call for urgent action from the scientific community. Science and technology have in the past played a vital role in improving public health. Today, with the tremendous potential of genomics and other advances in the life sciences, the contribution of science to improve public health and reduce global health disparities is more pertinent than ever before. Yet the benefits of modern medicine still have not reached millions of people in developing countries. It is crucial to recognize that science and technology can be used very effectively in partnership with public health practices in developing countries and can enhance their efficacy. The fight to improve global health needs, in addition to effective public health measures, requires rapid and efficient diagnostic tools; new vaccines and drugs, efficient delivery methods and novel approaches to therapeutics; and low-cost restoration of water soil and other natural resources. In 2002, the University of Toronto published a report on the "Top 10 Biotechnologies for Improving Health in Developing Countries". Here we review these new and emerging biotechnologies and explore how they can be used to support the goals of developing countries in improving health.
引用
收藏
页码:341 / 350
页数:10
相关论文
共 63 条
  • [1] Biotechnology and the UN's millennium development goals
    Acharya, T
    Daar, AS
    Singer, PA
    [J]. NATURE BIOTECHNOLOGY, 2003, 21 (12) : 1434 - 1436
  • [2] Adler M., 1996, Gazing into the oracle
  • [3] [Anonymous], Millennium Development Goals
  • [4] [Anonymous], 4 WHO
  • [5] Galactose-extended glycans of antibodies produced by transgenic plants
    Bakker, H
    Bardor, M
    Molthoff, JW
    Gomord, V
    Elbers, I
    Stevens, LH
    Jordi, W
    Lommen, A
    Faye, L
    Lerouge, P
    Bosch, D
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (05) : 2899 - 2904
  • [6] Balter M, 2001, SCIENCE, V291, P1873
  • [7] BLAKSLEE D, 1998, JAMA HIV AIDS INFORM
  • [8] Efficacy of RTS,S/ASO2 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia:: a randomised trial
    Bojang, KA
    Milligan, PJM
    Pinder, M
    Vigneron, L
    Alloueche, A
    Kester, KE
    Ballou, WR
    Conway, DJ
    Reece, WHH
    Gothard, P
    Yamuah, L
    Delchambre, M
    Voss, G
    Greenwood, BM
    Hill, A
    McAdam, KPWJ
    Tornieporth, N
    Cohen, JD
    Doherty, T
    [J]. LANCET, 2001, 358 (9297) : 1927 - 1934
  • [9] Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: Potential applications to microbicide development
    Boyd, MR
    Gustafson, KR
    McMahon, JB
    Shoemaker, RH
    OKeefe, BR
    Mori, T
    Gulakowski, RJ
    Wu, L
    Rivera, MI
    Laurencot, CM
    Currens, MJ
    Cardellina, JH
    Buckheit, RW
    Nara, PL
    Pannell, LK
    Sowder, RC
    Henderson, LE
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (07) : 1521 - 1530
  • [10] Breekveldt J, 1998, BIOTECHNOL DEV MONIT, P19